Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects

Journal of Clinical Pharmacology

Volumn 40, Issue 8, 2000, Pages 875-879

  Marino, Maria R ^a   Vachharajani, Nimish N ^a   Hadjilambris, Ophelia W ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRBESARTAN; SIMVASTATIN;

ACNE; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; NORMAL HUMAN;

ADULT; ANTIHYPERTENSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; BIPHENYL COMPOUNDS; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIXED FUNCTION OXYGENASES; SIMVASTATIN; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TETRAZOLES;

EID: 0033672869     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022009611     Document Type: Article

References (26)

1. 1 subtype angiotensin II receptor antagonist
2. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension
3. Dose-related efficacy of irbesartan for hypertension: An integrated analysis
4. Safety of irbesartan in the treatment of mild to moderate systemic hypertension
5. Rate and extent of left ventricular hypertrophy regression: A comparison of angiotensin II blockade with irbesartan and beta-blockade
6. The Irbesartan type II diabetic nephropathy trial: Study design and baseline patient characteristics
7. Safety and efficacy of irbesartan in patients with hypertension and renal insufficiency
8. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure
9. Irbesartan compared with lisinopril in patients with mild to moderate heart failure
10. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure
11. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes
12. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s
13. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
14. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
15. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
16. Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry
17. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time
18. The use of non-parametric methods in the statistical analysis of the two-period change-over design
19. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: An in vitro investigation with human liver preparations
20. Effect of nifedipine on the steady-state pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects
21. Irbesartan does not affect the steady-state pharmacodynamics and pharmacokinetics of warfarin